ES2527210T3 - Células etiquetadas para su uso como un control interno funcional en ensayos de detección de células raras - Google Patents

Células etiquetadas para su uso como un control interno funcional en ensayos de detección de células raras Download PDF

Info

Publication number
ES2527210T3
ES2527210T3 ES10179790.0T ES10179790T ES2527210T3 ES 2527210 T3 ES2527210 T3 ES 2527210T3 ES 10179790 T ES10179790 T ES 10179790T ES 2527210 T3 ES2527210 T3 ES 2527210T3
Authority
ES
Spain
Prior art keywords
rare
cell
sample
rare cells
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10179790.0T
Other languages
English (en)
Inventor
Leon W. M. M. Terstappen
Galla Chandra Rao
Herman Rutner
Paul A. Liberti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Janssen Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Diagnostics LLC filed Critical Janssen Diagnostics LLC
Application granted granted Critical
Publication of ES2527210T3 publication Critical patent/ES2527210T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/005—Pretreatment specially adapted for magnetic separation
    • B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un método para detectar y enumerar células raras en una población de células mezcladas, siendo la presencia de dichas células raras en dicha población indicativa de la severidad de una enfermedad, que comprende: a) Preparar una muestra inmunomagnética en la que una muestra de sangre obtenida de un sujeto de prueba se mezcla con partículas magnéticas, dicha muestra comprende una población de células mezcladas que se cree que contiene dichas células raras y dichas partículas magnéticas se acoplan a un ligando que reacciona específicamente con un determinante de las células raras para la exclusión sustancial de otros componentes de la muestra. b) Poner en contacto dicha muestra inmunomagnética con, al menos, un reactivo que marca un determinante de las células raras; y c) analizar las células raras marcadas para determinar la presencia y el número de cualquiera de las células raras en la muestra inmunomagnética, el mayor número de células raras presentes en dicha muestra, la mayor severidad de la enfermedad, donde la célula de control tiene determinantes en común con las células raras y en la que la membrana de dicha célula de control se encuentra marcada de forma detectable y los componentes celulares y restos antigénicos de la célula de control han sido estabilizados durante un período de hasta seis meses mediante la exposición a un fijador, donde, opcionalmente, dicha célula rara es una célula cancerígena y dicha enfermedad es cáncer.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
ES10179790.0T 2001-03-07 2002-03-07 Células etiquetadas para su uso como un control interno funcional en ensayos de detección de células raras Expired - Lifetime ES2527210T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/801,471 US20010018192A1 (en) 1998-02-12 2001-03-07 Labeled cells for use as an internal functional control in rare cell detection assays
US801471 2001-03-08

Publications (1)

Publication Number Publication Date
ES2527210T3 true ES2527210T3 (es) 2015-01-21

Family

ID=25181182

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10179790.0T Expired - Lifetime ES2527210T3 (es) 2001-03-07 2002-03-07 Células etiquetadas para su uso como un control interno funcional en ensayos de detección de células raras
ES02739098T Expired - Lifetime ES2357101T3 (es) 2001-03-07 2002-03-07 Celulas marcadas para su uso como control funcional interno en ensayos de detección de celulas raras.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02739098T Expired - Lifetime ES2357101T3 (es) 2001-03-07 2002-03-07 Celulas marcadas para su uso como control funcional interno en ensayos de detección de celulas raras.

Country Status (10)

Country Link
US (1) US20010018192A1 (es)
EP (2) EP1429603B1 (es)
JP (1) JP2004534210A (es)
AT (1) ATE490466T1 (es)
AU (1) AU2002311773A1 (es)
DE (1) DE60238493D1 (es)
DK (1) DK2280283T3 (es)
ES (2) ES2527210T3 (es)
PT (1) PT2280283E (es)
WO (1) WO2002077604A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282350B2 (en) 1998-02-12 2007-10-16 Immunivest Corporation Labeled cell sets for use as functional controls in rare cell detection assays
HK1042338B (zh) * 1998-10-29 2005-03-04 Cell Works Diagnostics Inc. 信号细胞的多标记表征
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
WO2003075007A2 (en) * 2002-03-01 2003-09-12 Cardiff & Vale National Health Service Trust Methods for absolute cell counting
CA2500392C (en) 2002-09-27 2012-11-27 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
ES2784011T3 (es) 2002-10-16 2020-09-21 Streck Inc Procedimiento y dispositivo para recoger y preservar las células para su análisis
WO2004076643A2 (en) 2003-02-27 2004-09-10 Immunivest Corporation CIRCULATING TUMOR CELLS (CTC’s): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
WO2005028663A2 (en) * 2003-09-18 2005-03-31 Immunivest Corporation Operator independent programmable sample preparation and analysis system
CA2535922A1 (en) * 2003-09-23 2005-04-07 University Of Missouri Methods of synthesizing polynucleotides using thermostable enzymes
US20050181353A1 (en) * 2004-02-17 2005-08-18 Rao Galla C. Stabilization of cells and biological specimens for analysis
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070128668A1 (en) * 2005-12-01 2007-06-07 Larry Burg Quantitative use of tracer cells
US8337755B2 (en) 2006-03-13 2012-12-25 Veridex, Llc Operator independent programmable sample preparation and analysis system
PT2027470E (pt) 2006-06-02 2013-01-28 Pfizer Prod Inc Ensaio de células tumorais circulantes
CN101583722A (zh) 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
US8110101B2 (en) 2007-08-30 2012-02-07 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
US7828968B2 (en) 2007-08-30 2010-11-09 Veridex, Llc Method and apparatus for imaging target components in a biological sample using permanent magnets
MX2010005811A (es) * 2007-11-27 2010-06-09 Veridex Llc Enumeracion automatica y caracterizacion de las celulas del melanoma circulantes en la sangre.
WO2010068812A1 (en) 2008-12-10 2010-06-17 Abqmr, Inc. Nuclear magnetic resonance apparatus, methods and associated technology
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
EP3290530B1 (en) 2009-02-18 2020-09-02 Streck Inc. Preservation of cell-free nucleic acids
CA2780536C (en) * 2009-11-09 2018-01-02 Streck, Inc. Stabilization of rna in and extracting from intact cells within a blood sample
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US9428547B2 (en) 2010-04-21 2016-08-30 Dna Electronics, Inc. Compositions for isolating a target analyte from a heterogeneous sample
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
EP2657346B1 (en) 2010-12-24 2017-08-23 ARKRAY, Inc. Method for detecting cancer cell
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
JP6133297B2 (ja) * 2011-09-06 2017-05-24 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 試料中の希少標的細胞のサイトメトリー検出のための方法及び組成物
US20150056649A1 (en) 2012-01-13 2015-02-26 Konica Minolta, Inc. Method for quantifying cell of interest in blood, and method for evaluating system for quantifying said cell
CN104981236B (zh) * 2012-09-27 2019-01-22 珠海圣美生物诊断技术有限公司 刺激敏感性微粒和使用方法
CA2885845C (en) * 2012-11-07 2019-10-29 Sandstone Diagnostics, Inc. Methods and devices for processing samples and counting cells
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US10376877B2 (en) 2013-02-07 2019-08-13 Sandstone Diagnostics, Inc. Automated sample processing, fluid distribution, and sedimentation assay
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
EP4136972A1 (en) 2013-07-24 2023-02-22 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
EP3027226A4 (en) * 2013-08-02 2016-07-27 Siemens Healthcare Diagnostics CELL-BASED CONTROL AND METHOD
JP6331524B2 (ja) * 2014-03-14 2018-05-30 日立化成株式会社 標準細胞液
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
JP6582486B2 (ja) * 2015-03-27 2019-10-02 コニカミノルタ株式会社 血液中の稀少細胞検出方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
US12378543B2 (en) 2017-10-19 2025-08-05 Streck Llc Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles
JP6485576B2 (ja) * 2018-04-19 2019-03-20 日立化成株式会社 標準細胞液
CA3135291A1 (en) * 2019-03-29 2020-10-08 The Brigham And Women's Hospital, Inc. Targeted synergistic cancer immunotherapy
JP7825568B2 (ja) * 2020-05-13 2026-03-06 ベクトン・ディキンソン・アンド・カンパニー 複合体パネルについての血液ベース対照

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188935A (en) * 1984-05-31 1993-02-23 Coulter Electronics, Inc. Reagent system and method for identification, enumeration and examination of classes and subclasses of blood leukocytes
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5597531A (en) * 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US5187099A (en) * 1986-10-29 1993-02-16 Coulter Corporation Control slide for immunoassay kit using a low-temperature melting paraffin
JP2619911B2 (ja) 1988-04-08 1997-06-11 東亜医用電子株式会社 網状赤血球測定装置用標準血液
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
US5698271A (en) * 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5610022A (en) * 1989-09-26 1997-03-11 City Of Hope Internal control for immunocytochemistry assay
IE76319B1 (en) 1990-07-23 1997-10-22 Becton Dickinson Co Preservation of cells as controls or standards in cellular analysis
US5478722A (en) * 1991-02-17 1995-12-26 The Curators Of The University Of Missouri Preserved cell preparations for flow cytometry and immunology
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
CA2129834A1 (en) * 1992-02-24 1993-08-25 Michael N. Elliott Suspension media for hematological composition and method for its use
WO1993018397A1 (en) * 1992-03-02 1993-09-16 Streck Laboratories, Inc. Reference control for use with manual and flow cytometric reticulocyte counting devices
US5763204A (en) * 1992-09-14 1998-06-09 Coulter Corporation Preparation of preserved, non-infectious control cell for use in the identification of a disease through blood testing
US5342754A (en) * 1992-09-14 1994-08-30 Coulter Corporation Preserved, non-infectious control cell for use in the identification of a disease through blood testing
WO1994016314A1 (en) * 1993-01-08 1994-07-21 Coulter Corporation Method of using preserved control cells in the calibration of fluorescent and light scatter measurements
EP0608987B1 (en) * 1993-01-26 2001-10-10 Becton, Dickinson and Company Method for detecting rare events
US5629933A (en) * 1995-06-07 1997-05-13 International Business Machines Corporation Method and system for enhanced communication in a multisession packet based communication system
JP3875754B2 (ja) * 1995-11-17 2007-01-31 シスメックス株式会社 フローサイトメータ用標準液
JP3996644B2 (ja) * 1996-06-07 2007-10-24 イムニベスト・コーポレイション 外部及び内部勾配を有する磁気分離
US5968831A (en) * 1996-10-29 1999-10-19 Coulter International Corp. Cell control used to confirm enzymatic activity
WO2000002049A1 (en) * 1998-07-01 2000-01-13 Nitto Denko Corporation Immunologic test method and immunologic test kit
JP2002541482A (ja) * 1999-04-13 2002-12-03 ヴィレックス アクチェンゲゼルシャフト 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用
GB0022017D0 (en) * 2000-09-08 2000-10-25 Univ Dundee Cell assays

Also Published As

Publication number Publication date
WO2002077604A2 (en) 2002-10-03
HK1152378A1 (en) 2012-02-24
DK2280283T3 (en) 2014-11-17
EP1429603B1 (en) 2010-12-01
EP1429603A4 (en) 2004-08-18
EP1429603A2 (en) 2004-06-23
JP2004534210A (ja) 2004-11-11
EP2280283A1 (en) 2011-02-02
AU2002311773A1 (en) 2002-10-08
PT2280283E (pt) 2015-02-03
DE60238493D1 (de) 2011-01-13
ES2357101T3 (es) 2011-04-18
ATE490466T1 (de) 2010-12-15
EP2280283B1 (en) 2014-10-15
US20010018192A1 (en) 2001-08-30
WO2002077604A3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
CN111465882B (zh) 用于测定的光学器件、装置和系统
Barrows et al. Immunochemical detection of human blood in feces
ES2548133T3 (es) Método de detección de niveles muy bajos de analito en una muestra fluida de película delgada contenida en una cámara de pequeño espesor
BRPI0111731C1 (pt) suporte sólido de imunoensaio, métodos de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e de produção de um suporte sólido de imunoensaio, e, kit de teste de imunodiagnóstico
ATE493929T1 (de) Integriertes blutprobemessgerät mit teststreifen
MY143768A (en) Enumeration of white blood cells
JP2004503760A5 (es)
DE60326336D1 (de) Vorrichtung und verfahren um gleichzeitig verschiedene antikörper und antigene nachzuweisen in klinischen, nahrungsmittel- und umwelt-proben
NO986043L (no) Fluorescent energioverf°ringsligand interaksjonsassay pÕ en lipid film
CO6280567A2 (es) Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion
EP1340730A4 (en) CERAMIC OPTICAL COMPONENTS AND METHOD FOR MANUFACTURING THE SAME
ATE331953T1 (de) Immunassayverfahren
ATE431424T1 (de) Reagenz zur urinanalyse und verfahren zur urinanalyse
BRPI0011449B8 (pt) composição de antígeno compreendendo tetramiristoil cardiolipina e 1-palmitoil-2-oleil-sn-glicero-3-fosfocolina e método para detectar anticorpos anti-lipoidais em uma amostra humana biológica in vitro
ATE240522T1 (de) Chemilumineszenz-immunoassay zum nachweis eines mit der chagas-erkränkung verbundenen analyts in einer probe
EP4509837A1 (en) Kit for detecting 25-hydroxyvitamin d in sample and detection method thereof
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
AR023634A1 (es) Una composicion que comprende al menos 6 peptidos recombinantes y/o sinteticos, un metodo para detectar la presencia de un anticuerpo de t.cruzi, en una muestra biologica, y un estuche de diagnostico para su deteccion
Bunce et al. Camera luminometer for use with luminescent assays
EA200700345A1 (ru) Обогащённое антитело для выявления микобактериальной инфекции, способы применения и диагностические тесты, применяющие такое антитело
ATE489632T1 (de) Antigennachweis
DK1141710T3 (da) Fremgangsmåde til detektering og/eller kvantificering af et specifikt IgE-antistof i en væskepröve
ES2558873T3 (es) Procedimiento y sistema de verificación de un biosensor electromecánico
CN204855521U (zh) 干式化学多合一检测试剂盒
CN205538643U (zh) 生化分析仪用进样装置